Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesalamine-associated thrombocytopenia.

R J Farrell1, M A Peppercorn, S N Fine

  • 1Department of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.

The American Journal of Gastroenterology
|August 13, 1999
PubMed
Summary

Mesalamine, a common ulcerative colitis treatment, can cause severe thrombocytopenia (low platelets) in rare cases. Regular blood monitoring is crucial for patients on mesalamine therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018
Same author

Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.

Alimentary pharmacology & therapeutics·2018
Same author

The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease.

Alimentary pharmacology & therapeutics·2014
Same author

Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.

Alimentary pharmacology & therapeutics·2014
Same author

The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method.

Alimentary pharmacology & therapeutics·2013
Same author

Macrophages promote epithelial repair through hepatocyte growth factor secretion.

Clinical and experimental immunology·2013

Area of Science:

  • Gastroenterology
  • Hematology
  • Clinical Pharmacology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
  • Mesalamine (5-aminosalicylic acid) is a primary treatment for UC.
  • Sulfasalazine, a related drug, is known for causing serious blood disorders.

Observation:

  • A 25-year-old woman with UC developed significant thrombocytopenia during oral mesalamine treatment.
  • Thrombocytopenia recurred upon rechallenge with mesalamine, suggesting causality.
  • Previous reports of mesalamine-induced hematological toxicity lacked rechallenge confirmation.

Findings:

  • This case demonstrates mesalamine can idiosyncratic ally cause marked thrombocytopenia.
  • Rechallenge confirmed the causal link between mesalamine and thrombocytopenia.

Related Experiment Videos

  • The study differentiates drug-induced toxicity from potential autoimmune contributions of IBD.

    • Implications:

    • Mesalamine, like sulfasalazine, carries a risk of serious hematological toxicity.
    • Routine complete blood count monitoring is recommended for all patients on mesalamine.
    • This highlights the importance of considering drug-induced thrombocytopenia in IBD patients presenting with low platelets.